Selective organ ischaemia/reperfusion identifies liver as the key driver of the post-injury plasma metabolome derangements.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
23
09
2018
accepted:
20
11
2018
pubmed:
13
2
2019
medline:
3
3
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Understanding the molecular mechanisms in perturbation of the metabolome following ischaemia and reperfusion is critical in developing novel therapeutic strategies to prevent the sequelae of post-injury shock. While the metabolic substrates fueling these alterations have been defined, the relative contribution of specific organs to the systemic metabolic reprogramming secondary to ischaemic or haemorrhagic hypoxia remains unclear. A porcine model of selected organ ischaemia was employed to investigate the relative contribution of liver, kidney, spleen and small bowel ischaemia/reperfusion to the plasma metabolic phenotype, as gleaned through ultra-high performance liquid chromatography-mass spectrometry-based metabolomics. Liver ischaemia/reperfusion promotes glycaemia, with increases in circulating carboxylic acid anions and purine oxidation metabolites, suggesting that this organ is the dominant contributor to the accumulation of these metabolites in response to ischaemic hypoxia. Succinate, in particular, accumulates selectively in response to the hepatic ischemia, with levels 6.5 times spleen, 8.2 times small bowel, and 6 times renal levels. Similar trends, but lower fold-change increase in comparison to baseline values, were observed upon ischaemia/reperfusion of kidney, spleen and small bowel. These observations suggest that the liver may play a critical role in mediating the accumulation of the same metabolites in response to haemorrhagic hypoxia, especially with respect to succinate, a metabolite that has been increasingly implicated in the coagulopathy and pro-inflammatory sequelae of ischaemic and haemorrhagic shock.
Sections du résumé
BACKGROUND
Understanding the molecular mechanisms in perturbation of the metabolome following ischaemia and reperfusion is critical in developing novel therapeutic strategies to prevent the sequelae of post-injury shock. While the metabolic substrates fueling these alterations have been defined, the relative contribution of specific organs to the systemic metabolic reprogramming secondary to ischaemic or haemorrhagic hypoxia remains unclear.
MATERIALS AND METHODS
A porcine model of selected organ ischaemia was employed to investigate the relative contribution of liver, kidney, spleen and small bowel ischaemia/reperfusion to the plasma metabolic phenotype, as gleaned through ultra-high performance liquid chromatography-mass spectrometry-based metabolomics.
RESULTS
Liver ischaemia/reperfusion promotes glycaemia, with increases in circulating carboxylic acid anions and purine oxidation metabolites, suggesting that this organ is the dominant contributor to the accumulation of these metabolites in response to ischaemic hypoxia. Succinate, in particular, accumulates selectively in response to the hepatic ischemia, with levels 6.5 times spleen, 8.2 times small bowel, and 6 times renal levels. Similar trends, but lower fold-change increase in comparison to baseline values, were observed upon ischaemia/reperfusion of kidney, spleen and small bowel.
DISCUSSION
These observations suggest that the liver may play a critical role in mediating the accumulation of the same metabolites in response to haemorrhagic hypoxia, especially with respect to succinate, a metabolite that has been increasingly implicated in the coagulopathy and pro-inflammatory sequelae of ischaemic and haemorrhagic shock.
Identifiants
pubmed: 30747701
pii: 2018.0188-18
doi: 10.2450/2018.0188-18
pmc: PMC6774928
doi:
Substances chimiques
Succinic Acid
AB6MNQ6J6L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-356Subventions
Organisme : NIGMS NIH HHS
ID : P50 GM049222
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008315
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007171
Pays : United States
Organisme : NHLBI NIH HHS
ID : UM1 HL120877
Pays : United States
Références
Life Sci. 1987 Sep 14;41(11):1375-82
pubmed: 3626761
J Trauma Acute Care Surg. 2015 Apr;78(4):742-51
pubmed: 25807403
Nature. 2014 Nov 20;515(7527):431-435
pubmed: 25383517
Platelets. 2012;23(1):60-8
pubmed: 21736422
J Surg Res. 2015 May 15;195(2):390-5
pubmed: 25777826
Shock. 2016 Aug;46(2):173-82
pubmed: 26863033
J Trauma Acute Care Surg. 2017 Oct;83(4):635-642
pubmed: 28463938
PLoS One. 2014 Sep 05;9(9):e106647
pubmed: 25191961
Cell. 2016 Feb 25;164(5):884-95
pubmed: 26919427
Nature. 2013 Apr 11;496(7444):238-42
pubmed: 23535595
Biochim Biophys Acta. 2016 Aug;1857(8):1086-1101
pubmed: 26971832
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4483-5
pubmed: 3380802
J Surg Res. 2011 Oct;170(2):314-8
pubmed: 21550053
Blood Transfus. 2016 May;14(2):185-94
pubmed: 27177401
Mol Biosyst. 2013 Mar;9(3):431-9
pubmed: 23340987
J Exp Med. 2016 Aug 22;213(9):1655-62
pubmed: 27481132
J Trauma. 2005 Jan;58(1):1-6
pubmed: 15674142
Shock. 2015 Aug;44 Suppl 1:114-22
pubmed: 25692254
Natl Vital Stat Rep. 2016 Feb 16;64(2):1-119
pubmed: 26905861
Kidney Blood Press Res. 2012;35(5):373-81
pubmed: 22487906
Nutr Hosp. 2001 Sep-Oct;16(5):176-82; discussion 175-6
pubmed: 11708288
Surgery. 2006 Sep;140(3):404-12
pubmed: 16934602
PLoS One. 2016 Sep 22;11(9):e0163021
pubmed: 27657885
J Clin Biochem Nutr. 2010 Mar;46(2):126-34
pubmed: 20216945
Histol Histopathol. 1999 Oct;14(4):1321-40
pubmed: 10506947
Cardiovasc Res. 2016 Jul 15;111(2):134-41
pubmed: 27194563
J Thromb Haemost. 2011 Feb;9(2):361-72
pubmed: 21143371
Am J Physiol Regul Integr Comp Physiol. 2015 Jun 15;308(12):R1034-44
pubmed: 25876652
J Proteome Res. 2011 Jan 7;10(1):277-87
pubmed: 21105667
J Am Heart Assoc. 2016 Sep 24;5(9):null
pubmed: 27664804
Sci Rep. 2013;3:2532
pubmed: 23982459
J Trauma Acute Care Surg. 2016 Dec;81(6):1012-1019
pubmed: 27602903
J Transl Med. 2015 Aug 05;13:253
pubmed: 26242576
J Trauma Acute Care Surg. 2017 Sep;83(3):491-495
pubmed: 28590356
J Trauma. 2010 Jul;69(1):31-40
pubmed: 20622576
Clin J Am Soc Nephrol. 2006 May;1(3):441-7
pubmed: 17699243
Crit Care. 2005 Oct 5;9(5):R591-5
pubmed: 16277723
Purinergic Signal. 2013 Sep;9(3):427-32
pubmed: 23584760
Int Rev Cell Mol Biol. 2012;298:229-317
pubmed: 22878108